SCHEMBL3016700

SCHEMBL3016700

Cc1ccc(C)c(-c2csc(N3CCN(S(=O)(=O)c4cccc(F)c4)CC3)n2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MAPT P10636 2/20 0.53
USP2 O75604 2/20 0.53
RECQL P46063 1/20 0.53
HSD17B10 Q99714 1/20 0.53
LMNA P02545 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
RAB9A P51151 1/20 0.47
MAPK1 P28482 2/20 0.47
TDP1 Q9NUW8 1/20 0.45
GFER P55789 1/20 0.45
NPC1 O15118 1/20 0.44
GBA1 P04062 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019761 0.90 ALDH1A1 (0.55) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3007427 0.89 ALDH1A1 (0.68) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3011194 0.89 AR (0.56) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3018393 0.89 AR (0.56) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3015616 0.88 POLB (0.54) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3010061 0.87 ALDH1A1 (0.54) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3004138 0.87 ALDH1A1 (0.68) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3014924 0.87 AR (0.64) ARSMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL2999057 0.86 MAPT (0.65) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3022029 0.86 ALDH1A1 (0.55) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.